Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.

A multicenter study of 638 cases of community-acquired pneumonia due to Streptococcus pneumoniae (SP-CAP) was performed to assess current levels of resistance. Of the pneumococcal strains, 35.7% had an minimum inhibitory concentration (MIC) of penicillin of > or =0.12 microg/mL (3 isolates had an MIC of 4 microg/mL), 23.8% had an MIC of erythromycin of 128 microg/mL, and 22.2% were multidrug resistant. Logistic regression determined that chronic pulmonary disease (odds ratio [OR], 1.44], human immunodeficiency virus infection (OR, 1.98), clinically suspected aspiration (OR, 2.12), and previous hospital admission (OR, 1.69) were related to decreased susceptibility to penicillin, and previous admission (OR, 1.89) and an MIC of penicillin of MIC > or =0.12 microg/mL (OR, 15.85) were related to erythromycin resistance (MIC, > or =1 microg/mL). The overall mortality rate was 14.4%. Disseminated intravascular coagulation, empyema, and bacteremia were significantly more frequent among patients with penicillin-susceptible SP-CAP. Among isolates with MICs of penicillin of > or =0.12 microg/mL, serotype 19 was predominant and was associated with a higher mortality rate. In summary, the rate of resistance to beta -lactams and macrolides among S. pneumoniae that cause CAP remains high, but such resistance does not result in increased morbidity.

[1]  J. Castillo,et al.  Bioestadística para las ciencias de la salud ( , 2004 .

[2]  F. Baquero,et al.  Antibiotic consumption and resistance selection in Streptococcus pneumoniae. , 2002, The Journal of antimicrobial chemotherapy.

[3]  M. Jacobs In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P. Reiss,et al.  Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Hutchinson Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.

[6]  R. Lütticken,et al.  Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. , 2002, The Journal of antimicrobial chemotherapy.

[7]  F. Baquero,et al.  Antimicrobial Susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenesIsolates and Their Ecological Relationships: Results of a 1-Year (1998–1999) Multicenter Surveillance Study in Spain , 2001, Antimicrobial Agents and Chemotherapy.

[8]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .

[9]  P. Rhomberg,et al.  Antimicrobial Resistance among Clinical Isolates ofStreptococcus pneumoniae in the United States during 1999–2000, Including a Comparison of Resistance Rates since 1994–1995 , 2001, Antimicrobial Agents and Chemotherapy.

[10]  V. Cheng,et al.  Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[12]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[13]  F. Baquero,et al.  Influences of Different Factors on Prevalence of Ciprofloxacin Resistance in Streptococcus pneumoniae in Spain , 2000, Antimicrobial Agents and Chemotherapy.

[14]  T. Marrie,et al.  Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. , 2000, The Journal of infectious diseases.

[15]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Schuchat,et al.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. , 2000, Archives of internal medicine.

[17]  A. Schuchat,et al.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. , 2000, American journal of public health.

[18]  D. Felmingham,et al.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.

[19]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[20]  Inger,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[21]  J. Liñares,et al.  Fluoroquinolone resistance in Streptococcus pneumoniae. , 1999, The New England journal of medicine.

[22]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[23]  J. Justman,et al.  Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  S. Dowell,et al.  Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  R. de Groot,et al.  Hospital-related outbreak of infection with multidrug-resistant Streptococcus pneumoniae in the Netherlands. , 1999, The Journal of hospital infection.

[26]  A. Torres,et al.  Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. , 1999, American journal of respiratory and critical care medicine.

[27]  Pan‐Chyr Yang,et al.  Extremely High Incidence of Macrolide and Trimethoprim-Sulfamethoxazole Resistance among Clinical Isolates ofStreptococcus pneumoniae in Taiwan , 1999, Journal of Clinical Microbiology.

[28]  A. Rossi,et al.  Risk Factors and Course of Illness Among Children With Invasive Penicillin-resistant Streptococcus pneumoniae , 1999 .

[29]  F. Baquero,et al.  Antimicrobial Resistance of 1,113Streptococcus pneumoniae Isolates from Patients with Respiratory Tract Infections in Spain: Results of a 1-Year (1996–1997) Multicenter Surveillance Study , 1999, Antimicrobial Agents and Chemotherapy.

[30]  A. Rossi,et al.  Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. , 1999, Pediatrics.

[31]  F. Baquero,et al.  Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. , 1999, Antimicrobial agents and chemotherapy.

[32]  I. Jado,et al.  Evolution of Streptococcus pneumoniaeSerotypes and Antibiotic Resistance in Spain: Update (1990 to 1996) , 1998, Journal of Clinical Microbiology.

[33]  M. Pfaller,et al.  Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  E. Choi,et al.  Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  G. Campbell,et al.  Drug-resistant Streptococcus pneumoniae. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  S. Buckingham,et al.  Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. , 1998, The Journal of pediatrics.

[37]  J. Córdoba-Doña,et al.  Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  J. R. Parsons,et al.  Bacteremia With Streptococcus pneumoniae: Implications for Therapy and Prevention , 1996 .

[39]  R. Breiman,et al.  Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. , 1996, JAMA.

[40]  S. Chevret,et al.  Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  I. Friedland Comparison of the response to antimicrobial therapy of penicillin‐resistant and penicillin‐susceptible pneumococcal disease , 1995, The Pediatric infectious disease journal.

[42]  C. Cabellos,et al.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. , 1995, The New England journal of medicine.

[43]  E. Bouza,et al.  Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  J. Garau,et al.  Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  A. Fenoll,et al.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. , 1991, Reviews of infectious diseases.

[46]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[47]  David W. Hosmer,et al.  Best subsets logistic regression , 1989 .

[48]  Gordon Cook,et al.  11. Applied Categorical Data Analysis , 1988 .

[49]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.